New Appoach targets Cancer Stem Cells and uses tens of thousands of animal models

Stemcentrx, has raised $500 million and is valued at $3 billion, people familiar with its finances say, a nearly unprecedented value for a company with no revenue, facing the usual R and D obstacles, and that almost no one has heard of. Silicon Valley is …

[Read the full article here]

Comments are closed.